Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Am J Hematol. 2015 Mar 2;90(4):320–326. doi: 10.1002/ajh.23937

Table 1.

Event-free survival (EFS) and overall survival (OS) of study cohort (n=149)

Predictors
		Event-free survival		Overall survival
	N	5-yr EFS ± SE	P value	5-yr OS ± SE	P value
All patients	149	50.8 ±5.5		73.1 ± 4.7
Original diagnosis
MAA	58	58.0 ± 8.9	0.004	78.1 ± 6.6	0.003
SAA	50	54.3 ± 8.9		82.2 ± 7.4
vSAA	41	36.8 ± 8.8		55.2 ± 9.0
Consensus diagnosis
RCC	30	71.3 ± 11.0	0.3^~	84.9 ± 8.8	0.3^~
AA	28	52.5 ± 13.7	0.3^~	72.5 ± 11.5	0.3^~
Other	10	58.3 ± 21.7		80.0 ± 20.7
Not sufficient to evaluate	6	75.0 ± 21.6		100
Unknown	75	40.3 ± 6.2		65.6 ± 6.2
IST only patients	91	34.6 ± 7.0		66 ± 6.7
IST therapy
Triple therapy	51	51.5 ± 8.5	0.006	87.8 ± 5.5	<0.0001
Other	40	16.3 ± 7.4	0.006	38.2 ± 10.0	<0.0001
Triple IST
Yr diagnosed: <2000	21	43.0 ± 12.2	0.4	82.1 ± 9.6	0.3
Yr diagnosed: ≥2000	30	58.1 ± 10.0	0.4	91.5 ± 6.3	0.3

^~

log rank test comparison of RCC vs. AA

SE = standard (error)